XTX Topco Ltd Invests $1.30 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• XTX Topco Ltd has acquired 19,342 shares of TransMedics Group, Inc., valued at approximately $1.3 million, reflecting a 0.06% ownership stake.
• Several institutional investors, including OneDigital Investment Advisors LLC and New York State Teachers Retirement System, significantly increased their positions in TransMedics Group during the first quarter of the year.
• TransMedics Group recently reported strong earnings, with an EPS of $0.92, exceeding analyst estimates, and year-over-year revenue growth of 37.7%.

XTX Topco Ltd acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 19,342 shares of the company's stock, valued at approximately $1,301,000. XTX Topco Ltd owned about 0.06% of TransMedics Group as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Vanguard Group Inc. boosted its holdings in shares of TransMedics Group by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares during the last quarter. FIL Ltd boosted its holdings in TransMedics Group by 28.0% in the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after acquiring an additional 218,961 shares during the last quarter. Braidwell LP acquired a new position in TransMedics Group in the fourth quarter valued at $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock valued at $56,307,000 after acquiring an additional 128,474 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after acquiring an additional 349,403 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Up 6.6%

TransMedics Group stock traded up $7.95 during midday trading on Monday, hitting $128.50. The stock had a trading volume of 1,901,994 shares, compared to its average volume of 1,287,210. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The stock has a market cap of $4.38 billion, a P/E ratio of 66.58 and a beta of 2.09. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The business has a fifty day moving average price of $124.51 and a 200 day moving average price of $95.50.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%. TransMedics Group's quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.35 earnings per share. Research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday. Piper Sandler restated an "overweight" rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Oppenheimer boosted their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Finally, Morgan Stanley boosted their price objective on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $123.00.

Insider Activity

In other news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the transaction, the director directly owned 732 shares of the company's stock, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.